71 related articles for article (PubMed ID: 8458020)
1. Role of nucleoside transport inhibition and endogenous adenosine in prevention of catecholamine induced death in rabbits.
Van Belle H; Ver Donck K; Verheyen W
Cardiovasc Res; 1993 Jan; 27(1):111-5. PubMed ID: 8458020
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.
Rongen GA; Smits P; Ver Donck K; Willemsen JJ; De Abreu RA; Van Belle H; Thien T
J Clin Invest; 1995 Feb; 95(2):658-68. PubMed ID: 7860749
[TBL] [Abstract][Full Text] [Related]
3. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor.
Van Belle H; Verheyen W; Ver Donck K; Janssen PA; Robertson JI
J Cardiovasc Pharmacol; 1992 Aug; 20(2):173-8. PubMed ID: 1381007
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of endogenous adenosine alter metabolism and enhance reduction in contractile function during low-flow ischemia: associated changes in expression of Ca(2+)-ATPase and phospholamban.
Sommerschild HT; Lunde PK; Deindl E; Jynge P; Ilebekk A; Kirkebøen KA
J Mol Cell Cardiol; 1999 Oct; 31(10):1897-911. PubMed ID: 10525427
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischaemic and blood reperfused rabbit heart.
Galiñanes M; Qiu Y; Van Belle H; Hearse DJ
Cardiovasc Res; 1993 Jan; 27(1):90-5. PubMed ID: 8458038
[TBL] [Abstract][Full Text] [Related]
6. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.
Snoeck E; Ver Donck K; Jacqmin P; Van Belle H; Dupont AG; Van Peer A; Danhof M
J Pharmacol Exp Ther; 1998 Jul; 286(1):142-9. PubMed ID: 9655853
[TBL] [Abstract][Full Text] [Related]
7. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.
Snoeck E; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Van Belle H; Woestenborghs R; Crabbé R; Van Gool R; Dupont A; Heykants J
Br J Clin Pharmacol; 1996 Nov; 42(5):605-13. PubMed ID: 8951192
[TBL] [Abstract][Full Text] [Related]
8. High-grade nucleoside transport inhibition stimulates ventilation in humans.
Rongen GA; Smits P; Bootsma G; Ver Donck K; de Vries A; Thien T
J Clin Pharmacol; 1995 Apr; 35(4):357-61. PubMed ID: 7650223
[TBL] [Abstract][Full Text] [Related]
9. Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.
Böhm M; Weinhold C; Schwinger RH; Müller-Ehmsen J; Böhm D; Reichenspurner H; Reichart B; Erdmann E
Br J Pharmacol; 1994 May; 112(1):137-42. PubMed ID: 8032635
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping.
Chang-Chun C; Masuda M; Szabò Z; Szerafin T; Szècsi J; Van Belle H; Flameng W
J Thorac Cardiovasc Surg; 1992 Dec; 104(6):1602-9. PubMed ID: 1453724
[TBL] [Abstract][Full Text] [Related]
11. Cardiac contractile function following repetitive brief ischemia: effects of nucleoside transport inhibition.
Kirkebøen KA; Ilebekk A; Tønnessen T; Leistad E; Naess PA; Christensen G; Aksnes G
Am J Physiol; 1994 Jul; 267(1 Pt 2):H57-65. PubMed ID: 8048608
[TBL] [Abstract][Full Text] [Related]
12. Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity.
Paproski RJ; Visser F; Zhang J; Tackaberry T; Damaraju V; Baldwin SA; Young JD; Cass CE
Biochem J; 2008 Sep; 414(2):291-300. PubMed ID: 18462193
[TBL] [Abstract][Full Text] [Related]
13. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine.
Rongen GA; Lenders JW; Lambrou J; Willemsen JJ; Van Belle H; Thien T; Smits P
Hypertension; 1996 Apr; 27(4):933-8. PubMed ID: 8613271
[TBL] [Abstract][Full Text] [Related]
14. Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: role of purine release in ischemic and reperfusion injury.
Abd-Elfattah AS; Jessen ME; Lekven J; Wechsler AS
Mol Cell Biochem; 1998 Mar; 180(1-2):179-91. PubMed ID: 9546645
[TBL] [Abstract][Full Text] [Related]
15. Transport of endogenous nucleosides in guinea pig heart.
Dekanski D; Piperski V; Tasić J; Marković ID; Jokanović M; Stukalov P; Mitrović DM
Can J Physiol Pharmacol; 2004 Dec; 82(12):1061-7. PubMed ID: 15644947
[TBL] [Abstract][Full Text] [Related]
16. Effects of nucleoside transport inhibition on long-term ex vivo preservation of canine hearts.
Masuda M; Chang-Chun C; Möllhoff T; Van Belle H; Flameng W
J Thorac Cardiovasc Surg; 1992 Dec; 104(6):1610-7. PubMed ID: 1453725
[TBL] [Abstract][Full Text] [Related]
17. Effect of aminophylline on coronary functional hyperemia and myocardial adenosine.
Jones CE; Hurst TW; Randall JR
Am J Physiol; 1982 Sep; 243(3):H480-7. PubMed ID: 7114278
[TBL] [Abstract][Full Text] [Related]
18. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.
Snoeck E; Piotrovskij V; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Woestenborghs R; Van Belle H; Van Bortel L; Van Gool R; Dupont AG; Heykants J
Br J Clin Pharmacol; 1997 Jun; 43(6):603-12. PubMed ID: 9205820
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent antinociceptive interactions between opioids and nucleoside transport inhibitors.
Keil GJ; Delander GE
J Pharmacol Exp Ther; 1995 Sep; 274(3):1387-92. PubMed ID: 7562512
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside trapping during reperfusion prevents ventricular dysfunction, "stunning," in absence of adenosine. Possible separation between ischemic and reperfusion injury.
Abd-Elfattah AS; Jessen ME; Wechsler AS
J Thorac Cardiovasc Surg; 1994 Aug; 108(2):269-78. PubMed ID: 8041175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
